Rubin EH, Morris JC, Grant EA, Vendegna T. Very mild senile dementia of the Alzheimer type. I. Clinical assessment. Arch Neurol. 1989 Apr;46:379–82.
CAS
PubMed
Article
Google Scholar
Williams-Gray CH, Mason SL, Evans JR, Foltynie T, Brayne C, Robbins TW, et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry. 2013 Nov;84:1258–64.
PubMed
Article
Google Scholar
Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017 Aug 3;390:1664–75.
CAS
PubMed
Article
Google Scholar
Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, et al. Mild cognitive impairment. Lancet. 2006 Apr 15;367:1262–70.
PubMed
Article
Google Scholar
Pritchard JC. A treatise on insanity. 1837.
Google Scholar
Senescent KRALVA. forgetfulness: benign and malignant. Can Med Assoc J. 1962 Feb 10;86:257–60.
Google Scholar
Levy R. Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization. Int Psychogeriatr. 1994;6:63–8.
CAS
PubMed
Article
Google Scholar
Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology. 1991 Jul;41:1006–9.
CAS
PubMed
Article
Google Scholar
Reisberg B, Ferris SH, de Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982 Sep;139:1136–9.
CAS
PubMed
Article
Google Scholar
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270–9.
PubMed
PubMed Central
Article
Google Scholar
Ritchie K. Mild cognitive impairment: an epidemiological perspective. Dialogues Clin Neurosci. 2004 Dec;6:401–8.
PubMed
PubMed Central
Google Scholar
Tomaszewski FS, Cahn-Weiner DA, Harvey DJ, et al. Longitudinal changes in memory and executive functioning are associated with longitudinal change in instrumental activities of daily living in older adults. Clin Neuropsychol. 2009;23:446–61.
Article
Google Scholar
Kluger A, Ferris SH, Golomb J, Mittelman MS, Reisberg B. Neuropsychological prediction of decline to dementia in nondemented elderly. J Geriatr Psychiatry Neurol. 1999;12:168–79.
CAS
PubMed
Article
Google Scholar
Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005 Jun 9;352:2379–88.
CAS
PubMed
Article
Google Scholar
Geslani DM, Tierney MC, Herrmann N, Szalai JP. Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer's disease. Dement Geriatr Cogn Disord. 2005;19:383–9.
PubMed
Article
Google Scholar
Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study. Neurology. 2001 Jan 9;56:37–42.
CAS
PubMed
Article
Google Scholar
Artero S, Tierney MC, Touchon J, Ritchie K. Prediction of transition from cognitive impairment to senile dementia: a prospective, longitudinal study. Acta Psychiatr Scand. 2003 May;107:390–3.
CAS
PubMed
Article
Google Scholar
Backman L, Small BJ, Fratiglioni L. Stability of the preclinical episodic memory deficit in Alzheimer's disease. Brain. 2001 Jan;124:96–102.
CAS
PubMed
Article
Google Scholar
Jack CR Jr, Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999 Apr 22;52:1397–403.
PubMed
PubMed Central
Article
Google Scholar
Krasuski JS, Alexander GE, Horwitz B, Daly EM, Murphy DGM, Rapoport SI, et al. Volumes of medial temporal lobe structures in patients with Alzheimer's disease and mild cognitive impairment (and in healthy controls). Biol Psychiatry. 1998 Jan;43(1):60–8.
CAS
PubMed
Article
Google Scholar
Chetelat G, Desgranges B, de lS V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology. 2003;60:1374–7.
CAS
PubMed
Article
Google Scholar
De SS, de Leon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging. 2001 Jul;22:529–39.
Article
Google Scholar
Gold M. Phase II clinical trials of anti-amyloid beta antibodies: When is enough, enough? Alzheimers Dement (N Y ). 2017;3:402–9.
Google Scholar
Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain. 2004;127:550–60.
PubMed
Article
Google Scholar
Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010 Sep 21;75:1062–9.
CAS
PubMed
PubMed Central
Article
Google Scholar
Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 2005 Oct 25;65:1239–45.
PubMed
Article
Google Scholar
Yarnall AJ, Breen DP, Duncan GW, Khoo TK, Coleman SY, Firbank MJ, et al. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology. 2014 Jan 28;82:308–16.
PubMed
PubMed Central
Article
Google Scholar
•• Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012;27:349–56. This paper describes the proposed diagnostic criteria for MCI in Parkinson’s disease following a Movement Disorder Society commissioned task force. These are now the definitive criteria in use in studies of PD-MCI.
PubMed
PubMed Central
Article
Google Scholar
Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, et al. MDS task force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord. 2011 Aug 15;26:1814–24.
PubMed
PubMed Central
Article
Google Scholar
• Kalbe E, Rehberg SP, Heber I, et al. Subtypes of mild cognitive impairment in patients with Parkinson's disease: evidence from the LANDSCAPE study. J Neurol Neurosurg Psychiatry. 2016;87:1099–105. This is a large-scale prospective multicentre study of PD-MCI, including 269 patients. The authors demonstrate that the dominant phenotype is non-amnestic.
Busse A, Hensel A, Guhne U, Angermeyer MC, Riedel-Heller SG. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology. 2006 Dec 26;67:2176–85.
CAS
PubMed
Article
Google Scholar
Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology. 2009 Mar 31;72:1121–6.
CAS
PubMed
Article
Google Scholar
Marras C, Armstrong MJ, Meaney CA, Fox S, Rothberg B, Reginold W, et al. Measuring mild cognitive impairment in patients with Parkinson's disease. Mov Disord. 2013 May;28:626–33.
PubMed
PubMed Central
Article
Google Scholar
Cholerton BA, Zabetian CP, Wan JY, Montine TJ, Quinn JF, Mata IF, et al. Evaluation of mild cognitive impairment subtypes in Parkinson's disease. Mov Disord. 2014 May;29:756–64.
PubMed
PubMed Central
Article
Google Scholar
Kehagia AA, Barker RA, Robbins TW. Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis. Neurodegener Dis. 2013;11:79–92.
PubMed
Article
Google Scholar
Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009;132:2958–69.
PubMed
Article
Google Scholar
Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord. 2006;21:1343–9.
PubMed
Article
Google Scholar
Domellof ME, Ekman U, Forsgren L, Elgh E. Cognitive function in the early phase of Parkinson's disease, a five-year follow-up. Acta Neurol Scand. 2015;132:79–88.
CAS
PubMed
Article
Google Scholar
• Pedersen KF, Larsen JP, Tysnes OB, Alves G. Natural course of mild cognitive impairment in Parkinson disease: A 5-year population-based study. Neurology 2017.This is a prospective follow-up study of incident Parkinson’s disease, including 178 patients. Importantly, the authors highlight the challenge of baseline MCI, as 27.8% of people with baseline PD-MCI had reverted to normal cognition at 5 year follow-up.
Hoogland J, Boel JA, de Bie RMA, Geskus RB, Schmand BA, Dalrymple-Alford JC, et al. Mild cognitive impairment as a risk factor for Parkinson's disease dementia. Mov Disord. 2017 Jul;32:1056–65.
PubMed
Article
Google Scholar
•• Darweesh SKL, Wolters FJ, Postuma RB, et al. Association Between Poor Cognitive Functioning and Risk of Incident Parkinsonism: The Rotterdam Study. JAMA Neurol 2017. In this prospective cohort study of 7386 individuals without Parkinson’s disease the authors showed that cognitive dysfunction was present before the onset of Parkinson’s disease and that poor global cognition is a risk factor for the development of Parkinson’s. This calls into question the very definition of Parkinson’s dementia that is classically thought to arise after the onset of motor symptoms.
Siderowf A, Stern MB. Premotor Parkinson's disease: clinical features, detection, and prospects for treatment. Ann Neurol. 2008 Dec;64(Suppl 2):S139–47.
PubMed
Google Scholar
Nagy A, Hardaker E, Bestwick JP, et al. Cognition in the PREDICT-PD cohort. 2017.
Google Scholar
Weintraub D, Chahine LM, Hawkins KA, Siderowf A, Eberly S, Oakes D, et al. Cognition and the course of prodromal Parkinson's disease. Mov Disord. 2017 Oct 24;32:1640–5.
CAS
PubMed
Article
Google Scholar
Anang JB, Nomura T, Romenets SR, Nakashima K, Gagnon JF, Postuma RB. Dementia predictors in Parkinson disease: a validation study. J Parkinsons Dis. 2017;7:159–62.
PubMed
Article
Google Scholar
Jozwiak N, Postuma RB, Montplaisir J, Latreille V, Panisset M, Chouinard S, et al. REM sleep behavior disorder and cognitive impairment in Parkinson's disease. Sleep. 2017 Aug 1;40
Hu MT, Szewczyk-Krolikowski K, Tomlinson P, et al. Predictors of cognitive impairment in an early stage Parkinson's disease cohort. Mov Disord. 2014;29:351–9.
PubMed
PubMed Central
Article
Google Scholar
Gjerstad MD, Aarsland D, Larsen JP. Development of daytime somnolence over time in Parkinson's disease. Neurology. 2002;58:1544–6.
CAS
PubMed
Article
Google Scholar
Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003;60:652–6.
CAS
PubMed
Article
Google Scholar
Compta Y, Marti MJ, Ibarretxe-Bilbao N, et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord. 2009;24(15):2203–10.
PubMed
Article
Google Scholar
Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, et al. CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord. 2010;25(15):2682–5.
PubMed
PubMed Central
Article
Google Scholar
Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T. Amyloid-beta and alpha-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease. Parkinsonism Relat Disord. 2015;21:758–64.
PubMed
Article
Google Scholar
Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology. 2010 Sep 21;75:1055–61.
CAS
PubMed
PubMed Central
Article
Google Scholar
Alves G, Lange J, Blennow K, Zetterberg H, Andreasson U, Forland MG, et al. CSF Abeta42 predicts early-onset dementia in Parkinson disease. Neurology. 2014 May;82(20):1784–90.
CAS
PubMed
Article
Google Scholar
Backstrom DC, Eriksson DM, Linder J, et al. Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease. JAMA Neurol. 2015;72:1175–82.
PubMed
Article
Google Scholar
Yu SY, Zuo LJ, Wang F, Chen ZJ, Hu Y, Wang YJ, et al. Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study. BMC Neurol. 2014;14:113.
PubMed
PubMed Central
Article
Google Scholar
Mollenhauer B, Zimmermann J, Sixel-Doring F, et al. Monitoring of 30 marker candidates in early Parkinson disease as progression markers. Neurology. 2016;87:168–77.
PubMed
PubMed Central
Article
Google Scholar
Gonzalez-Redondo R, Garcia-Garcia D, Clavero P, et al. Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process. Brain. 2014;137:2356–67.
PubMed
PubMed Central
Article
Google Scholar
Bohnen NI, Koeppe RA, Minoshima S, Giordani B, Albin RL, Frey KA, et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med. 2011 Jun;52:848–55.
CAS
PubMed
Article
Google Scholar
Tard C, Demailly F, Delval A, Semah F, Defebvre L, Dujardin K, et al. Hypometabolism in posterior and temporal areas of the brain is associated with cognitive decline in Parkinson's disease. J Parkinsons Dis. 2015;5:569–74.
PubMed
Article
Google Scholar
Ekman U, Eriksson J, Forsgren L, Mo SJ, Riklund K, Nyberg L. Functional brain activity and presynaptic dopamine uptake in patients with Parkinson's disease and mild cognitive impairment: a cross-sectional study. Lancet Neurol. 2012 Aug;11:679–87.
CAS
PubMed
Article
Google Scholar
Pellecchia MT, Picillo M, Santangelo G, Longo K, Moccia M, Erro R, et al. Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study. Acta Neurol Scand. 2015;131:275–81.
CAS
PubMed
Article
Google Scholar
Moore SF, Barker RA. Predictors of Parkinson's disease dementia: towards targeted therapies for a heterogeneous disease. Parkinsonism Relat Disord. 2014;20(Suppl 1):S104–7.
PubMed
Article
Google Scholar
Schrag A, Siddiqui UF, Anastasiou Z, Weintraub D, Schott JM. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study. Lancet Neurol. 2017 Jan;16:66–75.
CAS
PubMed
Article
Google Scholar
Gomperts SN, Locascio JJ, Marquie M, Santarlasci AL, Rentz DM, Maye J, et al. Brain amyloid and cognition in Lewy body diseases. Mov Disord. 2012 Jul;27:965–73.
PubMed
PubMed Central
Article
Google Scholar
Akhtar RS, Xie SX, Chen YJ, Rick J, Gross RG, Nasrallah IM, et al. Regional brain amyloid-beta accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. PLoS One. 2017;12:e0177924.
PubMed
PubMed Central
Article
CAS
Google Scholar
Song SK, Lee JE, Park HJ, Sohn YH, Lee JD, Lee PH. The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status. Mov Disord. 2011 Feb 1;26:289–96.
PubMed
Article
Google Scholar
Melzer TR, Watts R, MacAskill MR, et al. Grey matter atrophy in cognitively impaired Parkinson's disease. J Neurol Neurosurg Psychiatry. 2012 Feb;83:188–94.
PubMed
Article
Google Scholar
Pereira JB, Svenningsson P, Weintraub D, Bronnick K, Lebedev A, Westman E, et al. Initial cognitive decline is associated with cortical thinning in early Parkinson disease. Neurology. 2014 Jun 3;82:2017–25.
CAS
PubMed
PubMed Central
Article
Google Scholar
Hanganu A, Bedetti C, Degroot C, Mejia-Constain B, Lafontaine AL, Soland V, et al. Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson's disease longitudinally. Brain. 2014 Apr;137:1120–9.
PubMed
Article
Google Scholar
Foo H, Mak E, Yong TT, Wen MC, Chander RJ, Au WL, et al. Progression of subcortical atrophy in mild Parkinson's disease and its impact on cognition. Eur J Neurol. 2017 Feb;24:341–8.
CAS
PubMed
Article
Google Scholar
Hattori T, Orimo S, Aoki S, Ito K, Abe O, Amano A, et al. Cognitive status correlates with white matter alteration in Parkinson's disease. Hum Brain Mapp. 2012 Mar;33:727–39.
PubMed
Article
Google Scholar
Melzer TR, Watts R, MacAskill MR, et al. White matter microstructure deteriorates across cognitive stages in Parkinson disease. Neurology. 2013;80:1841–9.
CAS
PubMed
Article
Google Scholar
Agosta F, Canu E, Stefanova E, Sarro L, Tomić A, Špica V, et al. Mild cognitive impairment in Parkinson's disease is associated with a distributed pattern of brain white matter damage. Hum Brain Mapp. 2014;35:1921–9.
PubMed
Article
Google Scholar
Kamagata K, Motoi Y, Tomiyama H, Abe O, Ito K, Shimoji K, et al. Relationship between cognitive impairment and white-matter alteration in Parkinson's disease with dementia: tract-based spatial statistics and tract-specific analysis. Eur Radiol. 2013 Jul;23:1946–55.
PubMed
PubMed Central
Article
Google Scholar
Duncan GW, Firbank MJ, Yarnall AJ, Khoo TK, Brooks DJ, Barker RA, et al. Gray and white matter imaging: a biomarker for cognitive impairment in early Parkinson's disease? Mov Disord. 2016 Jan;31:103–10.
PubMed
Article
Google Scholar
Nigro S, Riccelli R, Passamonti L, Arabia G, Morelli M, Nisticò R, et al. Characterizing structural neural networks in de novo Parkinson disease patients using diffusion tensor imaging. Hum Brain Mapp. 2016;37:4500–10.
CAS
PubMed
Article
Google Scholar
Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord. 2014;29:634–50.
CAS
PubMed
PubMed Central
Article
Google Scholar
Jellinger KA. Neuropathology in Parkinson's disease with mild cognitive impairment. Acta Neuropathol. 2010;120:829–30.
PubMed
Article
Google Scholar
Adler CH, Caviness JN, Sabbagh MN, Shill HA, Connor DJ, Sue L, et al. Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol. 2010 Dec;120:827–8.
PubMed
PubMed Central
Article
Google Scholar
Lewy F. Paralysis agitans. I. Pathologische Anatomie. In: Lewandowsky M, Abelsdorff G, editors. Handbuch der Neurologie. Berlin: Springer-Verlag; 1912. p. 920–33.
Google Scholar
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997 Aug 28;388:839–40.
CAS
PubMed
Article
Google Scholar
Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, Collins C, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain. 2011 May;134:1493–505.
PubMed
PubMed Central
Article
Google Scholar
Sabbagh MN, Adler CH, Lahti TJ, Connor DJ, Vedders L, Peterson LK, et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord. 2009 Jul;23:295–7.
PubMed
PubMed Central
Article
Google Scholar
Howlett DR, Whitfield D, Johnson M, Attems J, O'Brien JT, Aarsland D, et al. Regional multiple pathology scores are associated with cognitive decline in Lewy body dementias. Brain Pathol. 2015 Jul;25:401–8.
CAS
PubMed
Article
Google Scholar
• Irwin DJ, Grossman M, Weintraub D, et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol 2017 Jan;16:55–65. This is a retrospective study of 213 patients with Parkinson’s followed-up to autopsy. The authors demonstrate that Alzheimer’s-type pathology is frequently seen in patients with Parkinson’s disease and that patients with higher burdens of Alzheimer’s neuropathology developed dementia more rapidly and had shorter survival times.
Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, et al. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A. 2001 Oct 9;98:12245–50.
CAS
PubMed
PubMed Central
Article
Google Scholar
Swirski M, Miners JS, de SR, et al. Evaluating the relationship between amyloid-beta and alpha-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease. Alzheimers Res Ther. 2014;6:77.
PubMed
PubMed Central
Article
CAS
Google Scholar
Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci. 2007 Feb 7;27:1405–10.
CAS
PubMed
Article
Google Scholar
Schulz-Schaeffer WJ. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 2010;120:131–43.
CAS
PubMed
PubMed Central
Article
Google Scholar
Whitfield DR, Vallortigara J, Alghamdi A, Howlett D, Hortobágyi T, Johnson M, et al. Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment. Neurobiol Aging. 2014;35:2836–44.
CAS
PubMed
Article
Google Scholar
Bereczki E, Francis PT, Howlett D, Pereira JB, Höglund K, Bogstedt A, et al. Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia. Alzheimers Dement. 2016;12:1149–58.
PubMed
Article
Google Scholar
Chung CY, Koprich JB, Siddiqi H, Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci. 2009;29:3365–73.
CAS
PubMed
PubMed Central
Article
Google Scholar
Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA, et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1985 May;48:413–21.
CAS
PubMed
PubMed Central
Article
Google Scholar
Gratwicke J, Kahan J, Zrinzo L, Hariz M, Limousin P, Foltynie T, et al. The nucleus basalis of Meynert: a new target for deep brain stimulation in dementia? Neurosci Biobehav Rev. 2013;37:2676–88.
PubMed
Article
Google Scholar
Wu H, Williams J, Nathans J. Complete morphologies of basal forebrain cholinergic neurons in the mouse. elife. 2014;3:e02444.
PubMed
PubMed Central
Google Scholar
Hale MW, Lowry CA. Functional topography of midbrain and pontine serotonergic systems: implications for synaptic regulation of serotonergic circuits. Psychopharmacology. 2011;213:243–64.
CAS
PubMed
Article
Google Scholar
Mattila PM, Roytta M, Lonnberg P, Marjamaki P, Helenius H, Rinne JO. Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathol. 2001;102:160–6.
CAS
PubMed
Google Scholar
Bohnen NI, Muller ML, Kotagal V, et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain. 2010 Jun;133:1747–54.
PubMed
PubMed Central
Article
Google Scholar
Shimada H, Hirano S, Shinotoh H, Aotsuka A, Sato K, Tanaka N, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology. 2009;73:273–8.
CAS
PubMed
Article
Google Scholar
Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. Brain. 1992;115(Pt 6):1701–25.
PubMed
Article
Google Scholar
Dubois B, Pilon B, Lhermitte F, Agid Y. Cholinergic deficiency and frontal dysfunction in Parkinson's disease. Ann Neurol. 1990;28:117–21.
CAS
PubMed
Article
Google Scholar
Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012;3:CD006504.
Google Scholar
Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi K, et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain. 2008;131:642–50.
PubMed
Article
Google Scholar
Sara SJ. The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci. 2009 Mar;10:211–23.
CAS
PubMed
Article
Google Scholar
Del TK, Braak H. Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia. J Neurol Neurosurg Psychiatry. 2013;84:774–83.
Article
Google Scholar
Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM. L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology. 1992;107:394–404.
CAS
PubMed
Article
Google Scholar
Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol. 2010;9:1200–13.
PubMed
Article
Google Scholar
Lee AC, Harris JP, Calvert JE. Impairments of mental rotation in Parkinson's disease. Neuropsychologia. 1998;36:109–14.
CAS
PubMed
Article
Google Scholar
Weintraub D, Hauser RA, Elm JJ, Pagan F, Davis MD, Choudhry A. Rasagiline for mild cognitive impairment in Parkinson's disease: a placebo-controlled trial. Mov Disord. 2016;31:709–14.
CAS
PubMed
Article
Google Scholar
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. Abolishing the 1-year rule: how much evidence will be enough? Mov Disord. 2016;31:1623–7.
PubMed
Article
Google Scholar
Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007;22:1689–707.
PubMed
Article
Google Scholar
McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology. 2017;89:88–100.
PubMed
PubMed Central
Article
Google Scholar
Weil RS, Pappa K, Schade RN, Schrag AE, Bahrami B, Schwarzkopf DS, et al. The cats-and-dogs test: a tool to identify visuoperceptual deficits in Parkinson's disease. Mov Disord. 2017;32:1789–90.
PubMed
PubMed Central
Article
Google Scholar
Li Z, Yu Z, Zhang J, Wang J, Sun C, Wang P, Zhang J. Impact of rivastigmine on cognitive dysfunction and falling in parkinson's disease patients. Eur Neurol. 2015;74(1-2):86–91.
Mamikonyan E, Xie SX, Melvin E, Weintraub D. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. Mov Disord. 2015;30:912–8.
CAS
PubMed
Article
Google Scholar
Weintraub D, Mavandadi S, Mamikonyan E, Siderowf AD, Duda JE, Hurtig HI, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75:448–55.
CAS
PubMed
PubMed Central
Article
Google Scholar
Kehagia AA, Housden CR, Regenthal R, Barker RA, Müller U, Rowe J, et al. Targeting impulsivity in Parkinson's disease using atomoxetine. Brain. 2014 Jul;137:1986–97.
PubMed
PubMed Central
Article
Google Scholar
Lindholm D, Pham DD, Cascone A, Eriksson O, Wennerberg K, Saarma M. C-Abl inhibitors enable insights into the pathophysiology and neuroprotection in Parkinson's disease. Front Aging Neurosci. 2016;8:254.
PubMed
PubMed Central
Article
Google Scholar
Schenk DB, Koller M, Ness DK, Griffith SG, Grundman M, Zago W, et al. First-in-human assessment of PRX002, an anti-alpha-synuclein monoclonal antibody, in healthy volunteers. Mov Disord. 2017;32:211–8.
CAS
PubMed
Article
Google Scholar
Leung IH, Walton CC, Hallock H, Lewis SJ, Valenzuela M, Lampit A. Cognitive training in Parkinson disease: a systematic review and meta-analysis. Neurology. 2015;85:1843–51.
PubMed
PubMed Central
Article
Google Scholar
Reynolds GO, Otto MW, Ellis TD, Cronin-Golomb A. The therapeutic potential of exercise to improve mood, cognition, and sleep in Parkinson's disease. Mov Disord. 2016;31:23–38.
PubMed
Article
Google Scholar
Petzinger GM, Fisher BE, McEwen S, Beeler JA, Walsh JP, Jakowec MW. Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease. Lancet Neurol. 2013;12:716–26.
PubMed
PubMed Central
Article
Google Scholar
Cruise KE, Bucks RS, Loftus AM, Newton RU, Pegoraro R, Thomas MG. Exercise and Parkinson's: benefits for cognition and quality of life. Acta Neurol Scand. 2011;123:13–9.
CAS
PubMed
Article
Google Scholar
Uc EY, Doerschug KC, Magnotta V, Dawson JD, Thomsen TR, Kline JN, et al. Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting. Neurology. 2014;83:413–25.
PubMed
PubMed Central
Article
Google Scholar
Nadeau A, Lungu O, Duchesne C, et al. A 12-week cycling training regimen improves gait and executive functions concomitantly in people with Parkinson's disease. Front Hum Neurosci. 2016;10:690.
PubMed
Google Scholar
Altmann LJ, Stegemoller E, Hazamy AA, et al. Aerobic exercise improves mood, cognition, and language function in Parkinson's disease: results of a controlled study. J Int Neuropsychol Soc. 2016;22:878–89.
PubMed
Article
Google Scholar
van der Kolk NM, De Vries NM, Penko AL, et al. A remotely supervised home-based aerobic exercise programme is feasible for patients with Parkinson's disease: results of a small randomised feasibility trial. J Neurol Neurosurg Psychiatry 2017.